scholarly article | Q13442814 |
P50 | author | Isabella Sperduti | Q37383620 |
Henrik J. Ditzel | Q41135530 | ||
Mariano Provencio | Q53051637 | ||
Antonio Passaro | Q60687407 | ||
Sara Pilotto | Q62554605 | ||
Trever G Bivona | Q90929253 | ||
Carles Codony-Servat | Q91318922 | ||
P2093 | author name string | Jie Yang | |
Santiago Viteri | |||
Noemi Reguart | |||
Mariacarmela Santarpia | |||
Niki Karachaliou | |||
Rafael Rosell | |||
Caicun Zhou | |||
Jia Wei | |||
Peng Cao | |||
Xuefei Li | |||
Sonia Rodriguez | |||
Alain Vergnenegre | |||
Alberto Verlicchi | |||
Chunping Hu | |||
Xueting Cai | |||
Patrick C Ma | |||
Enric Carcereny | |||
Chiara Lazzari | |||
Andres Felipe Cardona | |||
Jose Luis Ramirez | |||
Jose Miguel Sanchez | |||
Imane Chaib | |||
Ana Drozdowskyj | |||
Cristina Queralt | |||
Itziar de Aguirre | |||
Carles Codony Servat | |||
Charo Garcia Campelo | |||
Christina Teixido | |||
Filipo de Marinis | |||
Guillermo Lopez Vivanco | |||
Kirstine Jacobson | |||
Migual Angel Molina | |||
Raimon Puig de la Bellacasa | |||
Roger Estrada | |||
P2860 | cites work | β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis | Q24306274 |
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas | Q24669579 | ||
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer | Q28259999 | ||
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 | Q28637521 | ||
Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents | Q30502341 | ||
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. | Q33861952 | ||
A gp130-Src-YAP module links inflammation to epithelial regeneration | Q34465259 | ||
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function | Q35895556 | ||
Signaling networks assembled by oncogenic EGFR and c-Met | Q36392991 | ||
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies | Q37058831 | ||
Roles of unphosphorylated STATs in signaling | Q37118445 | ||
Genetics and biomarkers in personalisation of lung cancer treatment | Q38131166 | ||
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. | Q38971290 | ||
TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers. | Q39036426 | ||
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 | ||
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations | Q39712642 | ||
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokin | Q45021806 | ||
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. | Q54620289 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P577 | publication date | 2017-09-01 | |
P1433 | published in | Journal of the National Cancer Institute | Q400279 |
P1476 | title | Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. | |
P478 | volume | 109 |
Q54939484 | A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. |
Q41471047 | Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC) |
Q90572093 | Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer? |
Q48183995 | Brain metastases in patients with EGFR-mutant non-small-cell lung cancer |
Q59798144 | Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC |
Q43991475 | Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. |
Q50056486 | Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis |
Q58093858 | Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer |
Q43651454 | Dual roles of yes-associated protein (YAP) in colorectal cancer |
Q55314894 | Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. |
Q91798036 | Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy |
Q83225269 | Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC |
Q90555965 | ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer |
Q92424714 | Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy |
Q93351826 | Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) |
Q49501422 | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. |
Q64116828 | Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer |
Q49340076 | Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization |
Q64054076 | Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway |
Q97538337 | Mechanisms of resistance to osimertinib |
Q65000281 | Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway. |
Q61799008 | Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer |
Q92593655 | Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma |
Q38598893 | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy |
Q64238500 | Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis |
Q45822425 | Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). |
Q52317592 | STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. |
Q52317261 | TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. |
Q47828321 | TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. |
Q60908274 | The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer |
Q47100314 | The combination of checkpoint immunotherapy and targeted therapy in cancer |
Q90713517 | The prognostic value of YAP1 on clinical outcomes in human cancers |
Q92809901 | Tumor mutation burden and recurrent tumors in hereditary lung cancer |
Q50112440 | Tumour heterogeneity and resistance to cancer therapies |
Q46915997 | Understanding and targeting resistance mechanisms in NSCLC. |
Q58607426 | Unique MicroRNA and mRNA Interactions in -Mutated Lung Adenocarcinoma |
Q49569691 | YAP regulates PD-L1 expression in human NSCLC cells |
Search more.